Shareholders to Vote on Significant Increase in Stock Incentive and ESPP Shares
ASMB has more than doubled off its 52-week low of $9.82.
Summary
Assembly Biosciences is asking shareholders to approve the authorization of an additional 1.715 million shares for its employee equity plans, which could lead to significant future dilution.
Key Events · Financing and Capital Events · ASMB
-
Proposed Share Increase for Stock Incentive Plan
Shareholders will vote on a proposal to increase the number of shares reserved for issuance under the Amended and Restated 2018 Stock Incentive Plan by 1,200,000 shares.
-
Proposed Share Increase for Employee Stock Purchase Plan
Shareholders will also vote on a proposal to increase the authorized number of shares reserved for issuance under the Second Amended and Restated 2018 Employee Stock Purchase Plan by 515,000 shares.
-
Potential Dilution
The combined proposals, if approved, would authorize the issuance of an additional 1,715,000 shares, representing a substantial potential future dilution for current stockholders.
Analysis · ASMB · Life Sciences
Assembly Biosciences is seeking shareholder approval for two proposals that would significantly increase the number of shares reserved for its employee equity plans. If approved, these amendments would authorize an additional 1,715,000 shares for issuance under the 2018 Stock Incentive Plan and the 2018 Employee Stock Purchase Plan. This represents a substantial potential future dilution for existing shareholders, even though it is a common practice for employee compensation and retention. Investors should monitor the outcome of the shareholder vote on June 4, 2026.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.7% of the 1872 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ASMB was trading at $28.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $448.9M. The 52-week trading range was $9.82 to $39.71. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.